• Relief Cardiovascular

  Participated · Series A · Jan 2025

  Relief Cardiovascular is a privately held medical device company and an inQB8 Medical Technologies portfolio company focused on improving outcomes for patients with heart failure. Its flagship product, the Relief System, is a transcatheter smart implant that uses a "puller" mechanism and integrated sensors to autonomously capture renal vein pressures and multiparametric data. The system is designed to both monitor renal pressures and therapeutically modulate them, providing physicians actionable data to optimize fluid management—including for diuretic-resistant heart failure. The company plans to use new funding to advance product development and to initiate a first-in-human feasibility study to evaluate the safety and efficacy of the Relief System. Relief Cardiovascular has closed a $12M Series A to support these activities and is advancing toward human clinical studies. The company was founded and incubated within inQB8 Medical Technologies and is based in Irvine, Calif.

• Feeling Great

  Participated · Seed · Aug 2024

  Feeling Great builds an AI-powered therapy app based on psychiatrist Dr. David Burns’ T.E.A.M. approach, offering interactive courses and a conversational chatbot to practice techniques for managing emotions. The app combines an empathy-focused AI model and an evaluation framework to assess whether the AI understands users. It launched out of beta with roughly 3,000 users, is available on Android and iOS, and will be offered to U.S. customers with a seven-day free trial then $99 per year. The company has 14 employees and plans to use new funding to accelerate product development and marketing. Future product plans include voice-based AI, long-term memory, an anonymous mode, and eventually pursuing a clinical offering and FDA approval.

• Limbix

  Participated · Series A · Dec 2021

  Limbix develops prescription digital therapeutics for adolescents, delivering its first product via smartphone. Last month the company launched SparkRx, a CBT-based program focused on behavioral activation for adolescent depression. Limbix reported positive clinical-trial results showing a statistically significant reduction in depression symptoms for users who completed the program as recommended. The company raised $15 million in a Series A2 and has $31 million in total funding to date. Proceeds will be used for commercialization and to double staff to approximately 60 employees by Q2 2022. With an expanded product and research team, Limbix plans to accelerate development and testing of new digital therapeutics targeting other common adolescent mental health disorders. Limbix develops Limbix Spark, a self-guided, cognitive behavioral therapy–based mobile program designed to treat adolescent depression and to be prescribed by pediatricians. The program was developed with clinical experts and direct input from teens and aims to reach the roughly 60% of teens with depression who do not receive care. The company says Limbix Spark could become the first prescription digital therapeutic for adolescents if cleared by the FDA. Limbix has partnered with the Duke Clinical Research Institute to run a large-scale pivotal clinical trial, with recruitment scheduled to begin later this year. The trial is described as a double-blind, sham-controlled, randomized controlled trial to evaluate safety and efficacy. Limbix is headquartered in San Francisco and emphasizes a cross-functional team of clinicians, product designers, researchers, and engineers. Limbix develops prescription digital therapeutics to treat adolescent mental health disorders. Its flagship product, Limbix Spark, is a multi-week cognitive behavioral therapy program focused on value-based activities that aim to elicit feelings of pleasure or mastery. Limbix Spark is positioned as the first prescription digital therapeutic designed to treat adolescents with depression and is intended for pediatrician prescription once FDA clearance is obtained. The company raised $9M in a Series A round led by GSR Ventures with participation from Sequoia Capital, Storm Ventures, NextGen Venture Partners and BIXINK Therapeutics. Limbix intends to use the funds for research and development of Limbix Spark. Ben Lewis is CEO and co-founder and the company is based in Palo Alto, California.

• Safely You

  Participated · Series A · Sep 2021

  SafelyYou sells an ambient, AI-powered camera-and-sensor platform that detects when residents might be falling and triggers text and phone alerts to on-call staff. The system does not require wearables and is paired with a remote clinical team that documents falls, reviews videos, conducts root-cause analyses, and issues recommendations. The clinical team has analyzed more than 300,000 on-the-ground events to help reduce future falls. Founder George Netscher says the technology originated in 2015 as part of his doctoral research and the company’s mission is to ensure the highest-quality care for seniors. SafelyYou nearly shut down during the COVID-19 pandemic but survived and now serves nearly 1,000 senior living communities. The company employs roughly 100 people and is San Francisco-based; new capital will support continued expansion. SafelyYou has developed a remote care platform combining real-time AI video technology with a 24/7 remote clinical team to detect and address resident falls. The product is targeted at senior living communities to reduce fall rates and emergency room visits. The company is led by founder and CEO George Netscher and is based in San Francisco, CA. SafelyYou is backed by investors including Eclipse Ventures, Foundation Capital, DCVC, Founders Fund, and Omega Healthcare Investors. The company obtained a $30 million venture loan facility from Horizon Technology Finance, with $10 million initially funded. It intends to use the loan proceeds to expand its business reach. SafelyYou develops an AI-enabled fall management platform that detects falls, analyzes patterns, and pairs technology with professional caregiver intervention to prevent future incidents for seniors and people with Alzheimer’s, dementia, or cognitive impairment. The system combines video review and AI-augmented pattern recognition, reviewing over 1,500 videos of on-the-ground events per month to generate personalized care plans. SafelyYou’s platform is reported to reduce falls by 40% and ER visits from falls by 80%, and a Belmont Village case study found fall-driven ER visits fell to 4% versus an industry average of 17–25%. Beyond detection and prevention, the technology assists caregivers with medication adherence, behavioral monitoring, false-alarm management, memory issues, and occupational therapy support. The company plans to expand availability of its fall-management technology to a wider range of older adults and scale deployments in senior-care facilities. Financially, SafelyYou closed a $30 million Series B in the announced round, bringing its total venture funding to approximately $70 million. SafelyYou offers an AI-enabled fall detection and prevention system specifically designed for memory care and residents with Alzheimer’s disease and related dementias. Its solution uses cameras that only activate when a fall is detected to protect privacy and limit liability. The platform provides post-fall video review to support unwitnessed falls, assist ER decision making, and perform root cause analysis to inform fall prevention. SafelyYou originated in 2015 as the doctoral research of CEO George Netscher at the UC Berkeley Artificial Intelligence Research Lab. The system is already deployed in numerous communities in North America. The company intends to use its new funding to scale its assisted living and skilled nursing business.

• Casca

  Participated · Series A · Nov 2019

  Casca develops customizable footwear using 3D-printed insoles and automated, decentralized manufacturing to create a more precise fit and reduce waste. The company debuted its Avro sneaker, which features a custom 3D-printed insole printed to customers’ arch and foot measurements. Customers can customize Avro through Casca’s iOS or Android app and receive shoes and insoles within 14 days. Casca says its manufacturing approach increases efficiency and aims to challenge traditional footwear production. The startup plans to open its first retail space in Vancouver later this month. Casca hopes to manufacture 100 percent custom-fit shoes by 2029.

No current team members are available.